Kruxagon

Omeprazole, the active ingredient in Kruxagon, is a proton pump inhibitor presented as an oral tablet for systemic use. It reduces gastric acid production and is used to manage conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication regimens, and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Kruxagon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch, ensuring reliable supply across multiple regions.

Omeprazole is a proton pump inhibitor that reduces gastric acid secretion, making it useful for several acid‑related disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief of heartburn and regurgitation, and promotes healing of esophageal irritation caused by acid exposure. - Peptic ulcer disease: facilitates ulcer healing by decreasing gastric acidity, thereby reducing further mucosal damage and allowing the ulcer margin to close. - Helicobacter pylori eradication: used as part of a triple or quadruple combination regimen, improving eradication rates by suppressing acid that protects the bacteria. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors, helping to prevent recurrent ulcers and acid‑related complications.

Omeprazole may be associated with a range of adverse reactions, varying from mild and transient to serious but uncommon events.

Common Side Effects: - Headache: mild headache reported in clinical use. - Diarrhea: loose stools occurring especially during initial therapy. - Nausea: feeling of queasiness or upset stomach. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Elevated liver enzymes: signs of hepatic irritation detectable in blood tests. - Low magnesium levels: may cause muscle cramps, irregular heartbeat, or seizures. - Increased risk of bone fracture: long‑term use linked to reduced calcium absorption. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

When prescribing omeprazole, clinicians should consider several precautionary measures to ensure safe and effective use. - Assess indication: confirm that acid suppression therapy is appropriate for the diagnosed condition. - Review medical history: consider prior hypersensitivity to proton pump inhibitors or related compounds. - Monitor long‑term use: reassess need after several months to avoid unnecessary exposure. - Check concomitant meds: be aware of drugs whose absorption or efficacy may change with altered gastric pH. - Evaluate renal or hepatic impairment: adjust dose if severe organ dysfunction is present. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect due to impaired activation. - Atazanavir and other protease inhibitors: markedly decreased absorption leading to therapeutic failure. - Methotrexate (high dose): increased serum levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: altered absorption may change serum concentrations. - Diazepam: increased plasma levels; dose adjustment may be needed. - Iron salts: decreased iron absorption; separate dosing by at least 2 hours.